Journal of Advanced Biomedical Sciences
JABS
Mon, Nov 3, 2025
[Archive]
Volume 15, Issue 4 (10-2025)
J Adv Biomed Sci. 2025, 15(4): 404-407 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yaghoobi N, Farjam M, Pezeshki B. Additive Effects of Ezetimibe and Statins in Managing Elevated LDL-C: An Approach to Reducing Cardiovascular Risk. J Adv Biomed Sci. 2025; 15 (4) :404-407
URL: http://jabs.fums.ac.ir/article-1-3158-en.html
URL: http://jabs.fums.ac.ir/article-1-3158-en.html
1- Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
2- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
3- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran ,babakpezeshki@yahoo.com
2- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
3- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran ,
Abstract: (156 Views)
Elevated low-density lipoprotein cholesterol (LDL-C) is a key modifiable risk factor for cardiovascular disease. While statins are the cornerstone of LDL-C-lowering therapy, their long-term use may result in dose-dependent adverse effects. Ezetimibe, a Niemann–Pick C1-Like 1 inhibitor, reduces intestinal cholesterol absorption and complements the reduction of hepatic cholesterol synthesis achieved through statin therapy. Evidence from major trials, including IMPROVE-IT, SHARP, RACING, and EWTOPIA 75, demonstrates that combination therapy achieves greater LDL-C reduction and provides modest improvements in clinical outcomes compared with statin monotherapy, while maintaining a favorable safety profile. The early initiation of combination therapy may permit the use of lower statin doses, thereby reducing adverse effects such as insulin resistance and hepatotoxicity. The co-administration of ezetimibe with statins, when implemented alongside guideline-recommended strategies, represents a rational and patient-centered approach for high-risk individuals. This strategy offers enhanced lipid control and improved safety outcomes relative to statin monotherapy.
Keywords: LDL, Ezetimibe, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Hyperlipidemias
Type of Study: Letter to the Editor |
Subject:
Pharmacology
Received: 2025/07/14 | Revised: 2025/11/1 | Accepted: 2025/09/27 | Published: 2025/11/1
Received: 2025/07/14 | Revised: 2025/11/1 | Accepted: 2025/09/27 | Published: 2025/11/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)